FDA Approved: BYETTA — Supplemental Application (AstraZeneca Pharmaceuticals LP)

View source ↗

Summary

The FDA approved a supplemental application for BYETTA (exenatide) submitted by AstraZeneca, resulting in labeling changes for the drug.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• BYETTA (Exenatide)

Snippet

SUPPL AP for BYETTA (EXENATIDE)